3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
pembrolizumab
304
Paclitaxel
206
Carboplatin
200
Gemcitabine
173
Cisplatin
139
Docetaxel
138
Cyclophosphamide
136
Nivolumab
129
Bevacizumab
118
Injections
111
fludarabine
96
atezolizumab
91
Pemetrexed
90
Dexamethasone
90
Cetuximab
90
Fluorouracil
84
Irinotecan
77
Rituximab
72
Capecitabine
72
venetoclax
71
Azacitidine
70
130-nm albumin-bound paclitaxel
67
Leucovorin
65
Fulvestrant
58
Oxaliplatin
57
durvalumab
56
Trastuzumab
56
Lenalidomide
55
Ipilimumab
55
Midazolam
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
INDUSTRY
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled